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Abstract: Background: There is a pressing need to expand the evidence base in geriatric lung oncology.
Most non-small cell lung cancers (NSCLCs) are diagnosed in the elderly, with approximately 15%
of cases affecting octogenarians. Treatment-related decisions are challenging in this population,
and the role of biologically driven therapies is still underrated. Methods: A single-institution
cohort of 76 NSCLCs from octogenarian patients was submitted to molecular analysis using a
next-generation sequencing (NGS) multigene panel, fluorescence in situ hybridization (FISH) analyses,
and immunohistochemistry for PD-L1 assessment. Treatment and clinical outcome data were
available for 33 patients. Results: Most cases (n = 66, 87%) harbored at least one genomic alteration.
EGFR and KRAS mutations were detected in 18 (24%) and 20 (26%) patients, respectively. No ALK
alterations were found, but in two patients ROS1 translocation was identified. Of 22 cases tested, 17
were positive for PD-L1 staining. Octogenarian patients who received tyrosine kinase inhibitors (TKIs)
based on molecular analysis showed clinical benefits, with long progression-free survival as expected
in TKI-treated younger cohorts. Conclusions: This study highlights the utility of molecular profiling
in all advanced-stage NSCLCs, regardless of the age at diagnosis, to drive personalized treatment.
The prevalence of druggable alterations and the clinical benefits obtained by biologically-driven
therapies in octogenarians were comparable to those of the younger NSCLC population.
Keywords: octogenarian; NSCLC; TKI therapy; NGS
1. Introduction
Lung cancer is the leading cause of cancer-specific mortality worldwide [1], and is typically
a disease of the elderly. The median age at diagnosis is 70 years, and almost 10% of patients are
older than 84 years [2]. Since the geriatric population has been increasing, the management of
elderly patients affected by lung cancer is of growing concern [3]. Old patients with cancer usually
have comorbidities and age-related physiological characteristics that make the choice of treatment
challenging. Systemic cytotoxic chemotherapy, which has been the standard treatment of advanced
lung cancer for decades, tends to be less-well-tolerated by elderly patients than by younger ones.
The development of specific therapies targeting driver alterations (e.g., EGFR mutations or ALK and
ROS1 rearrangements) has changed the treatment paradigm and natural history of non-small cell lung
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cancer (NSCLC) harboring these aberrations [4,5]. To date, limited data are available regarding the
safety and efficacy of these agents in the elderly population, and above all in octogenarian patients,
since they are underrepresented in clinical trials [6,7]. Nevertheless, in clinical practice, the evaluation
of tumor molecular features together with the clinical characteristics of octogenarian patients with
NSCLC may broaden the treatment options and drive a tailored clinical management of these patients.
In the present study, we report the molecular characterization of advanced NSCLC from
76 consecutive octogenarian patients who were referred to our institution over 19 months for
molecular diagnosis, following clinical requests. The molecular testing was performed using a
next-generation sequencing (NGS) panel including EGFR, KRAS, and BRAF genes, in addition to
fluorescence in situ hybridization (FISH) analyses for ALK, ROS1, MET, and immunohistochemical
(IHC) evaluation of PD-L1 expression. We sought to (i) evaluate the biological characteristics of NSCLC
occurring in octogenarian patients, which could lead to personalized treatments; and (ii) investigate
the potential clinical benefit of molecularly driven therapies in a subgroup of patients treated with
targeted treatment.
2. Materials and Methods
2.1. Patients
Of the 890 patients with advanced-stage (IIIb and IV) NSCLCs referred to the Molecular
Diagnostics Unit of the European Institute of Oncology from August 2016 to February 2018, 76 patients
over 80 years were included in this study. Molecular tests and IHC evaluation were required by
thoracic oncologists, and included the analysis of EGFR, KRAS, BRAF, ALK, ROS1, MET, and PD-L1
according to the international guidelines for molecular testing in lung cancer [8,9]. Patients’ age,
gender, smoking history, performance status (PS), and treatment regimens were collected from medical
records and are summarized in Table 1. Based on their smoking status, patients were categorized
as smokers, recent ex-smokers (more than 6 months but less than 15 years), long-term ex-smokers
(more than 15 years), and never-smokers (Table 1). Thirty-three patients (43%) were inpatients and
treated at the Division of Thoracic Oncology of the European Institute of Oncology. PS at diagnosis
was evaluated according to the Eastern Cooperative Oncology Group (ECOG) criteria [10]. Patients’
treatments included chemotherapy (vinorelbine, pemetrexed, or gemcitabine), local radiotherapy,
and anti-EGFR tyrosine kinase inhibitor (TKI) (erlotinib, gefitinib, or osimertinib) (Table 1). The best
response to treatment was evaluated according to Response Evaluation Criteria in Solid Tumors
(RECIST) [11].
All patients gave written informed consent regarding the storage of any biological specimens
collected in the course of diagnosis and the use of these samples for research purposes.
Table 1. Clinicopathological characteristics of patients included in the study.
Age Median (Range)
≥80 years old 82 (80–92)
Gender n (%)
Male 58 (76.3%)
Female 18 (23.7%)
Histology n (%)
Adenocarcinoma 66 (86.8%)
Adenosquamous carcinoma 2 (2.6%)
Non-squamous NSCLC 8 (10.6%)
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Table 1. Cont.
Age Median (Range)
Smoking Habit n (%)
Smokers 6 (7.9%)
Recent ex-smokers 14 (18.4%)
Long-term ex-smokers 16 (21.1%)
Never-smokers 18 (23.7%)
NA 22 (28.9%)
Performance Status (PS) n (%)
PS = 0 1 (1.3%)
PS = 1 20 (26.3%)
PS = 2 11 (14.5%)
PS > 2 5 (6.6%)
NA 39 (51.3)
Treatment Regimens n (%)
Chemotherapy 13 (17%)
Tyrosine kinase inhibitor 10 (13.2%)
Radiotherapy and/or best supportive care 10 (13.2%)
NA 43 (56.6%)
NA: data not available.
2.2. Next-Generation Sequencing Analysis
Five-micrometer-thick sections from representative formalin-fixed paraffin-embedded (FFPE)
tissue blocks (n = 63) and cytoblocks (n = 8) or smears (n = 5) were used for the analyses. The DNA was
extracted automatically with the Promega Maxwell instrument (Promega, Madison, WI, USA) using
the Promega Maxwell RSC DNA FFPE kit, and was quantified with the Quantus fluorometer (Promega,
Madison, WI, USA). The NGS mutational analysis was performed with the CE-IVD (CE-marked,
In-Vitro Diagnostics) Oncomine Solid Tumour DNA kit (ThermoFisher, Waltham, MA, USA).
This panel allowed for the simultaneous evaluation of the mutational status (single-nucleotide variants,
small insertions, and deletions) of 22 genes, namely EGFR, ALK, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3,
MET, DDR2, KRAS, PIK3CA, BRAF, AKT1, PTEN, NRAS, MAP2K1, STK11, NOTCH1, CTNNB1,
SMAD4, FBXW7, and TP53. The targeted NGS analysis was performed following the manufacturer’s
instructions. Briefly, 10 ng of genomic DNA was used for the library preparation. Sequencing was
performed on a Personal Genome Machine (PGM) sequencer or Ion S5 System (ThermoFisher, Waltham,
MA, USA), and data were analyzed using the Ion Reporter Analysis software v.5.2-5.10 (ThermoFisher,
Waltham, MA, USA). Quality metric filters were used as previously described [12]. Only variants
with an allele frequency ≥5% and those included in a public cancer gene mutation database (Cosmic:
http://cancer.sanger.ac.uk/cosmic; ClinVar: https://www.ncbi.nlm.nih.gov/clinvar; TCGA Cancer
Genome: http://cancergenome.nih.gov) were reported. Benign variants or polymorphisms were
not reported. Mutations were classified as level I variants, level II variants, and level III variants
according to their clinical relevance and/or availability of targeted therapy and the type of cancer
under investigation [12–15].
2.3. Fluorescence in Situ Hybridization Analysis
ALK and ROS1 gene rearrangements and MET amplification were evaluated by the standard
FISH method. Briefly, unstained sections obtained from FFPE blocks or cytoblocks were incubated
with an ALK and ROS1 dual-color probe (IQFISH Break Apart Probe Agilent Technologies, Santa Clara,
CA, USA). In each case, at least 100 tumor nuclei were evaluated. Cells were considered positive if a
break-apart pattern of orange and green signals, at least one single orange signal, or a combination of
both patterns were seen. Tumors with at least 15% of cells with ALK or ROS1 rearrangements were
defined as positive. In ambiguous or equivocal cases, ALK or ROS1 immunohistochemical stains (clone
D5F3, Ventana, Tucson, AZ, USA and clone D4D6, Cell Signaling, Danvers, MA, USA, respectively)
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were performed. The presence of MET gene amplification was evaluated using the MET IQFISH Probe
with CEP7 (Agilent Technologies, Santa Clara, CA, USA). Amplification was reported in cases with a
MET Probe/CEP7 Ratio ≥2 and/or gene copy number ≥5.
2.4. PD-L1 Immunohistochemical Analysis
PD-L1 expression was evaluated on tumor cells using the immunohistochemistry assay CE-IVD
PD-L1 IHC 22C3 pharmDx with the Agilent-Dako 22C3 clone developed on the Dako Autostainer Link
48 (Agilent Technologies, Santa Clara, CA, USA) as previously described [16]. The Tumor Proportion
Score (TPS) was used to classify the cases as negative (IHC positive staining <1% neoplastic cells),
1%–49% positive cells, or >50% positive cells.
3. Results
3.1. Molecular Profile of Advanced Non-Small Cell Lung Cancer in Octogenarian Patients
In our study population, 66 of 76 (87%) cases harbored at least one gene alteration, including
clinically relevant and cancer-related variants. The most frequently mutated genes were TP53 (37%),
KRAS (26%), and EGFR (24%) (Figure 1 and Table 2).
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Figure 1. Oncoprint plot showing the distribution of genomic alterations identified in the study cohort.
The co-occurrence of EGFR exon 19 deletion and T790M missense mutation was reported as a missense
mutation. Genes without genomic alterations were not reported.
Level I and level II alterations, defined by high clinical relevance for prognosis and/or target
therapy available in a clinical setting (level I) or clinical trials (level II), accounted for 62/106 (58.5%) of
genomic aberrations identified and involved EGFR, ROS1, KRAS, BRAF (1 case V600E), MET, NRAS,
ERBB2, PIK3CA, and AKT1 genes (Figure 1 and Table 2).
In detail, KRAS and EGFR mutations were reported in 20 and 18 NSCLC specimens, respectively.
All KRAS mutations identified affected exon 2.
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Mutations in EGFR included both TKI-sensitive mutations (n = 16), such as exon 19 deletions
(n = 8) and exon 21 L858R point mutation (n = 8); and TKI-resistant mutations, such as exon 20
insertions (n = 2). In four cases, a secondary T790M resistant mutation was detected during TKI
treatment. Concurrent EGFR, T790M, and L858R mutations were present at diagnosis in one patient
with no history of TKI therapy.
No ALK fusions were detected in our study cohort. ROS1 gene rearrangements were identified in
two cases, with a concurrent NRAS mutation or KRAS mutation.
Moreover, MET alterations were found in 12% of cases and included missense variants (n = 4),
exon 14 skipping mutations (n = 1), and gene amplifications (n = 4).
Overall concurrent genetic aberrations were found in 33 cases (Figure 1), including TP53 mutations
with either EGFR (n = 7) or KRAS (n = 4) mutations. Moreover, EGFR mutations were found in
association with alterations of MET (n = 2) and STK11 (n = 1) genes. Concurrent KRAS and STK11
mutations were identified in two cases.
PD-L1 evaluation was requested for a subgroup of octogenarian patients (n = 22, 29%), including
five negative cases (25%), seven cases (25%) with intermediate TPS between 1% and 49%, and ten
cases (50%) with diffuse PD-L1 expression (TPS > 50%) (Table 2). Among the 17 positive cases, five
had concurrent EGFR mutations, five had concurrent KRAS mutations, and two had concurrent
BRAF mutations.
Table 2. Frequencies of genomic alterations and PD-L1 expression detected in NSCLCs from the
octogenarian patients of the study.
Gene (No. of cases tested = 76) n (No. of cases)
EGFR mutation 18
ALK rearrangement 0
ROS1 rearrangement 2
KRAS mutation 20
MET mutation/amplification 9
BRAF mutation 4
ERBB2 mutation 3
Alterations in other genes 22
All genes wild-type 10
PD-L1 IHC (N. of cases tested = 22) n
TPS < 1% 5
TPS = 1%–49% 7
TPS > 50% 10
IHC: immunohistochemistry; TPS: Tumor Proportion Score.
3.2. Treatment Regimens and Clinical Outcome of Octogenarian Patients with Advanced Non-Small Cell
Lung Cancers
Treatment and follow-up data were available for thirty-three inpatients. Twenty-three of these
patients received an active treatment (Table 2). In ten cases, only radiotherapy or best supportive care
was given because of the presence of comorbidities or poor performance status, including four patients
with a PS of two, five patients with a PS of three, and one patient with a PS of one who had previously
undergone right nephrectomy for renal cell carcinoma. Data about targeted treatments were available
only for patients with EGFR mutations. The other actionable alterations (in ROS1, ERBB2, MET, and
BRAF) were found in NSCLC outpatients or inpatients with a poor PS, not eligible for enrollment in a
clinical trial or active treatment.
Among the patients with EGFR mutations, the majority were never-smokers or long-term
ex-smokers (n = 13/18 cases, 72.2%). Smoking habits were not assessed in the remaining cases.
A different distribution between males and females was not seen (8 males and 12 females).
Treatment and follow-up data were available for ten patients who received tyrosine kinase inhibitors
(TKIs), including erlotinib, gefitinib, or osimertinib, when a concurrent EGFR T790M mutation was
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detected. One patient was first-line treated with osimertinib because of the co-occurrence of L858R and
T790M mutations at diagnosis (patient #3, Figure 2 and Table 3). The median progression-free survival
(PFS) for patients receiving TKI as first-line therapy was 17 months, including five patients in whom
treatment was ongoing (Figure 2). One patient died of progressive disease after 4 months of treatment.
During first-line TKI therapy, two patients developed the EGFR T790M resistance mutation and
received osimertinib as second-line treatment. The best responses observed were complete responses
in two patients (#7 and #8, Figure 2), reached after four months of gefitinib and 5 months of osimertinib,
respectively. Both patients were still receiving treatment after 14 months of gefitinib and 15 months of
osimertinib, respectively.
Table 3. Clinical and molecular characteristics of the 23 inpatients who received active treatment.
Patient # Mutational Status PD-L1 TPS PerformanceStatus Treatment
1 EGFR p.Glu746_Ala750delEGFR p.Thr790Met >50% PS 0 TKIs—Gefitinib and Osimertinib
2 EGFR p.Glu746_Ala750delMET amplified >50% PS 1 TKI—Gefitinib
3
EGFR p.Leu858Arg
EGFR p.Thr790Met
TP53 p.Asn131Tyr
1%–49% PS 1 TKI—Osimertinib
4 EGFR p.Leu858ArgTP53 p.Pro80Ser NA PS 1 TKI—Gefitinib
5 EGFR p.Leu858Arg NA PS 2 TKI—Gefitinib
6 EGFR p.Glu746_Ala750del 1%–49% PS 1 TKI—Gefitinib
7 EGFR p.Leu858Arg NA PS 1 TKI—Gefitinib
8
EGFR
p.Glu746_Thr752delinsAla
EGFR p.Thr790Met
TP53 p.Cys176Tyr
SMAD4 p.Phe354Leu
NA PS 1 TKIs—Erlotinib and Osimertinib
9
EGFR p.Leu858Arg
TP53 p.Val157Phe
STK11 p.Phe354Leu
NA PS 1 TKI—Gefitinib
10 EGFR p.Glu746_Ala750delEGFR p.Thr790Met NA PS 1 TKIs—Erlotinib and Osimertinib
11 WT NA PS 1 Chemotherapy—Vinorelbine
12 WT <1% PS 2 Chemotherapy—Combination regimens *
13 WT <1% PS 1 Chemotherapy—Vinorelbine
14 KRAS p.Gly12Val <1% PS 2 Chemotherapy—Vinorelbine
15 TP53 p.Asn131Tyr NA PS 1 Chemotherapy—Vinorelbine
16 SMAD4 p.Gln256Leu NA PS 1 Chemotherapy—Combination regimens *
17 PIK3CA p.Glu545Lys NA PS 1 Chemotherapy—Vinorelbine
18 KRAS p.Gly12CysPIK3CA p.Glu545Lys NA PS 2 Chemotherapy—Vinorelbine
19 KRAS p.Gly12CysTP53 Glu349Ter <1% PS 2 Chemotherapy—Vinorelbine
20 KRAS p.Gly12AspTP53 p.Val216Met 1%–49% PS 1 Chemotherapy—Vinorelbine
21 KRAS p.Gly12ValSTK11 p.Asp194Tyr NA PS 2 Chemotherapy—Vinorelbine
22 KRAS p.Gly13CysSTK11 p.Arg331Trp >50% PS 2 Chemotherapy—Vinorelbine
23 TP53 p.Gys275PheERBB2 p.Ile767Met NA PS 1 Chemotherapy—Combination regimens *
#: Patient’s ID; TPS: Tumor Proportion Score; PS: performance status; TKI: tyrosine kinase inhibitor; WT: wild-type;
NA: data not available; *: combination regimens including gemcitabine-pemetrexed-carboplatin.
Thirteen patients received chemotherapy-based regimens, including metronomic vinorelbine
(n = 10) or platinum-based therapy (n = 3). The median PFS of these patients was 2 months (Figure 2).
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4. Discussion
Treatment-related decisions in octogenarians affected by NSCLC are challenging: the elderly could
have reduced tolerance of treatments because of limited physiological reserve or multiple comorbid
conditions, but they could also be under-treated based solely on biological age [6]. Case-by-case
clinical assessment in addition to tumor molecular analyses could lay the basis for tailored treatment
choices. However, few data are available regarding the real-life management of octogenarian patients
with NSCLC.
In the present study, we focused on a single-institution cohort of 76 consecutive octogenarian
patients affected by advanced NSCLC. All tumors were analyzed using an NGS multi-gene panel that
expands the tumor genetic portrait, including genes such as BRAF, ERBB2, KRAS, and MET in addition
to EGFR and ALK/ROS1, in accordance with recently updated recommendations [8,9]. Most cases
(86.8%) harbored at least one genetic alteration, and in only ten cases no genomic aberration was
detected in the genes tested. These data were consistent with our recent findings obtained in a larger
cohort of NSCLC patients, not selected by age at diagnosis [12]. Indeed, among 535 NSCLC patients,
we found that 82.4% harbored at least one NGS-detected mutation, compared to 85.5% within this
study cohort. In the present study, we reported level I and II variants in 65.8% of the cases, including
EGFR (24%) and KRAS (26%) mutations. In our previous series, level I and II variants were detected in
63.6% of cases, with KRAS and EGFR mutations present in 31% and 22% of the cases, respectively [12].
The differences in mutation distribution between the two series were not statistically significant (2 test
p > 0.05) and showed that the presence of specific tumor genetic aberrations was not related to the
age of the patients. Conversely, ALK fusions were not detected in our cohort, consistent with the
reported association between ALK translocation and the patients’ younger age [17,18]. Surprisingly,
we found ROS1 translocations in two patients. This rarest druggable alteration has been reported
in 1%–2% of NSCLCs [19,20], usually affecting never-smoker young female patients [19]. In our
cohort, two octogenarian males harbored a ROS1 translocation, and both had concurrent clinically
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relevant mutations (ROS1+/KRAS+ and ROS1+/NRAS+). Similar anecdotal cases of concurrent ROS1
rearrangements and KRAS mutations were recently reported [21,22], whereas no cases of ROS1
translocations and NRAS variants have been described so far. ROS1 gene rearrangements could be
targeted by TKIs, but KRAS/NRAS gene point mutations could lead to ineffective inhibition through
inactivation of the RAF/MEK/ERK signaling pathway. Given that these patients were both outpatients,
no data about therapeutic regimens or clinical outcomes were available.
In a subgroup of octogenarian patients, we also identified alterations in MET, BRAF, and ERBB2
genes, which may be targeted by specific therapies in a clinical setting or clinical trials [23,24]. Moreover,
we reported level III mutations that could be clinically significant. TP53 mutations have recently been
associated with prognosis or therapy response in patients with concomitant EGFR or KRAS mutations,
or ALK rearrangement [25]. Patients whose tumors harbored concurrent EGFR and TP53 mutations
showed a worse response rate to TKIs and worse progression-free survival [26]. KRAS+-TP53+ tumors
displayed a higher level of inflammatory markers and improved relapse-free survival [27].
In the octogenarians included in this study, EGFR mutated status was associated with
non-smoking, as in the general population of NSCLC patients. A TKI treatment was administered to
ten EGFR mutation-positive patients, who showed a PFS consistent with data from larger series of
NSCLC patients [28–35]. Although these series included patients ranging from 24 to 88 years old, the
elderly were underrepresented and specific data regarding octogenarians are limited. Previous studies
have reported on the safety and efficacy of TKIs in elderly patients, as shown by osimertinib treatment
for T790M-positive NSCLC [36] or erlotinib treatment for NSCLC after one or more platinum-based
chemotherapy regimens [37]. However, the definition of “elderly” is highly heterogeneous among
these studies, including patients ranging from 65 [37] to 75 years old [36]. Recently, a multicenter
real-world study (OCTOMUT) evaluated the tolerability and efficacy of TKIs in Caucasian octogenarian
patients with EGFR-mutated NSCLC [38]. The authors reported clinical outcomes and toxicity profiles
comparable to those in younger patients. The median PFS observed in that retrospective study was
11.9 months for patients treated with TKIs. Although the number of patients with follow-up data was
limited in our cohort, we observed a prolonged response in six of ten patients treated with TKI therapy.
Moreover, seven patients are receiving ongoing treatment.
During the past few years, the spectrum of therapeutic options for NSCLC patients with
no identified genomic aberrations has been enlarged. Besides standard chemotherapy regimens,
treatments with immune checkpoint inhibitors alone or in combination with chemotherapy have been
shown to be effective in selected patients with advanced NSCLC enrolled in clinical trials. However, in
the largest series, elderly patients were underrepresented, especially octogenarians [39]. The ELDERS
Study is a prospective pilot study evaluating the role of checkpoint inhibitors in patients ≥70 years
old [40]. Although there are some promising results, the real benefit of immunotherapy in this specific
population is still under debate. In this study population, only a few tumors were tested for tumor
PD-L1 expression (the only approved biomarker to select patients for immunotherapy in our country)
and were found to have the whole range of TPS scores. Retrospective collections of clinical data from a
large series of elderly individuals who received immunotherapies and, above all, prospective studies
focused on NSCLC patients ≥80 years old are warranted in order to clarify the role of immunotherapy
in the octogenarian population.
A major limitation of the present study is the relatively small cohort of patients analyzed. However,
we collected consecutive octogenarian patients affected by NSCLC who underwent tumor molecular
analyses for diagnostic purposes in a single institution. Another limitation is that treatment and
follow-up data were not available for all patients and were collected retrospectively from patients’
medical records. We reported data for thirty-three inpatients of the Division of Thoracic Oncology
of the European Institute of Oncology, including twenty-three patients who received molecularly
driven treatments. Although the small cohort prevented identification of any clinical or statistical
correlations and the retrospective analysis was not selected for the probability of survival, we reported
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interesting insights into the clinical course of octogenarian patients actively treated based on tumor
molecular characteristics.
5. Conclusions
This study highlights the utility of molecular analyses for all patients with advanced-stage NSCLC,
regardless of age at diagnosis, to guide clinical decisions. Except for ALK translocation, the distribution
of molecular alterations in the octogenarian population under investigation was very similar to that in
a younger population. Molecular analyses should be performed with multi-gene panels, following
the recent recommendations for molecular testing in NSCLC [8,9], to widen the number of predictive
markers that may be detected. Indeed, most of the NSCLCs analyzed in this study harbored at least
one actionable or clinically-relevant gene alteration. This information may guide clinical decisions
about active treatments for these patients with clinical benefits. In the era of precision medicine, age
itself may not represent a contraindication to evaluate the molecular characteristics of a tumor. Rather,
a comprehensive assessment of clinical, pathological, and molecular features of octogenarian patients
with NSCLC may improve the selection of tailored and effective treatments for this population.
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